<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656587</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS8758</org_study_id>
    <nct_id>NCT04656587</nct_id>
  </id_info>
  <brief_title>BPAP in Pediatric Asthma Pilot Study</brief_title>
  <official_title>Bilevel Positive Airway Pressure (BPAP) in Pediatric Asthma Exacerbations: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to study the effect and safety of bilevel positive airway pressure&#xD;
      (BPAP) in children with moderate to severe asthma exacerbations. The goal of this study is to&#xD;
      determine the feasibility of enrolling, randomizing, and completing data collection in at&#xD;
      least 30 participants over a one year period. The investigators will enroll children 5 to 17&#xD;
      years of age presenting to the emergency department with a moderate to severe asthma&#xD;
      exacerbation. Eligible participants will be randomized into two groups: standard therapy&#xD;
      (continuous albuterol) or standard therapy plus BPAP. The following data will be collected:&#xD;
      Pediatric Respiratory Assessment Measure (PRAM) score at 0, 2 and 4 hours, vital signs at 0,&#xD;
      2 and 4 hours, rate of adverse events and Pediatric Intensive Care Unit (PICU) admissions,&#xD;
      duration continuous albuterol, length of hospital stay, and rates of intubations or deaths.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of successfully enrolling, randomizing, and completing data collection in 30 participants within one year.</measure>
    <time_frame>One year</time_frame>
    <description>Feasibility defined as successfully enrolling, randomizing, and completing data collection in 30 participants within one year in the pediatric emergency department.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in PRAM Score</measure>
    <time_frame>At 2 and 4 hour time points</time_frame>
    <description>Difference in PRAM scores at 2 and 4 hours. PRAM scores range from 0 to 12 with a score of 4 or greater indicating moderate to severe disease. Decreasing scores reflect clinical improvement in response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Respiratory Rate</measure>
    <time_frame>At 2 and 4 hour time points</time_frame>
    <description>Difference in respiratory rate measured in breaths per minute (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Oxygen Saturation</measure>
    <time_frame>At 2 and 4 hour time points</time_frame>
    <description>Difference in percent oxygen saturation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Heart Rate</measure>
    <time_frame>At 2 and 4 hour time points</time_frame>
    <description>Difference in heart rate measured in beats per minute (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>At 2 and 4 hour time points</time_frame>
    <description>Difference in systolic and diastolic blood pressure measured in millimeters of mercury (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Duration of continuous beta-agonist therapy</measure>
    <time_frame>Until therapy is completed, approximately 24 hours</time_frame>
    <description>Difference in duration of continuous beta-agonist therapy measured in hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of PICU Admission</measure>
    <time_frame>Until hospital discharge, approximately 2 days</time_frame>
    <description>Rate of admissions from the Emergency Department (ED) to PICU versus home or to the pediatric floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Until hospital discharge, approximately 2 days</time_frame>
    <description>Length of stay, measured in days, in the ED, PICU, or hospital</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cumulative Number of Adverse Events</measure>
    <time_frame>Until hospital discharge, approximately 2 days</time_frame>
    <description>The total number of adverse events per arm will be reported. Adverse events include air leak syndrome, aspiration pneumonia, skin break down, hypotension, intubation, death or other adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma in Children</condition>
  <condition>Status Asthmaticus</condition>
  <arm_group>
    <arm_group_label>Standard Therapy (Control)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy plus BPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Philips Respironics V60 Non-invasive ventilator, BPAP</intervention_name>
    <description>Continuous albuterol will be administered through the BPAP circuit.</description>
    <arm_group_label>Standard Therapy plus BPAP</arm_group_label>
    <other_name>Philips Respironics V60 Non-invasive ventilator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.</description>
    <arm_group_label>Standard Therapy (Control)</arm_group_label>
    <arm_group_label>Standard Therapy plus BPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  5 to 17 years of age (inclusive) presenting to the Emergency Department (ED) with an&#xD;
             asthma exacerbation&#xD;
&#xD;
          -  Prior clinician diagnosis of asthma&#xD;
&#xD;
          -  PRAM score of 4 or greater after initial albuterol/atrovent back to backs, steroids,&#xD;
             +/- oxygen&#xD;
&#xD;
          -  Need for continuous nebulized albuterol therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypercapneic respiratory failure (partial pressure of carbon dioxide &gt; 60 mmHg)&#xD;
&#xD;
          -  Hypoxemic respiratory failure (SaO2 &lt; 90% with fraction of inspired oxygen &gt; 0.35)&#xD;
&#xD;
          -  Presence of a tracheostomy or baseline noninvasive ventilation requirement&#xD;
&#xD;
          -  Non-asthma causes of wheezing (foreign body, tracheomalacia, vocal cord dysfunction,&#xD;
             pulmonary edema, uncorrected congenital heart disease, cystic fibrosis)&#xD;
&#xD;
          -  Contra-indication to BPAP (facial trauma, uncontrollable vomiting, hypotension for&#xD;
             age, Glasgow Coma Scale (GCS) 8 or less, drowsiness or confusion, known or clinical&#xD;
             suspicion for pneumothorax, pneumomediastinum, or subcutaneous emphysema, pregnancy,&#xD;
             current weight &lt; 20kg)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick T Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick T Wilson, MD</last_name>
    <phone>212-305-8458</phone>
    <email>ptw2107@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick T Wilson, MD</last_name>
      <phone>212-305-8458</phone>
      <email>ptw2107@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michele E Smith, MD</last_name>
      <phone>212-305-8458</phone>
      <email>ms5376@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick T Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle E Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Patrick Wilson</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics and Population and Family Health</investigator_title>
  </responsible_party>
  <keyword>non-invasive ventilation</keyword>
  <keyword>BPAP</keyword>
  <keyword>continous albuterol</keyword>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

